Mealey's (December 21, 2015, 12:20 PM EST) -- BOSTON — Less than two months after the Zofran multidistrict litigation was created, GlaxoSmithKline LLC (GSK) on Dec. 11 filed a motion for summary judgment or dismissal on the grounds that an October response to a citizen petition filed with the Food and Drug Administration shows that agency would not approve the same warnings the plaintiffs say the nausea drug should have (In Re: Zofran [Ondansetron] Products Liability Litigation, MDL Docket No. 2657, No. 15-md-2657, D. Mass.).

(Zofran preemption brief available. Document #28-151217-014B.)

In a motion...